OctoPlus N.V. has announced that a process development and manufacturing contract has been signed with a pharmaceutical company headquartered in Denmark.
The undisclosed contract value will make a material contribution to OctoPlus' annual revenues.
Under the contract terms, we will perform process development and manufacturing of a microsphere-based formulation for our client.
At OctoPlus we provide formulation development and clinical material manufacturing services to biotech and pharmaceutical companies worldwide.
In addition to our expertise in formulation and manufacturing, we offer our clients drug delivery technologies for the development of controlled release versions of existing or new drugs.